Summary
The AI statements provided are largely generic descriptions of meropenem/vaborbactam mechanisms and do not map to the specific FDA-approved indication, dosing, contraindications, warnings/precautions, interactions, or administration details contained in the supplied label excerpts. One statement about approved use in 'complicated infections' is only broadly aligned and lacks label specificity.
Category Scores
Accurate Statements
Vabomere is a brand name for a combination antibiotic medicine.
Supported by label excerpt identifying VABOMERE as a drug and a fixed-dose combination (Drug/Active ingredients excerpt).
Vabomere combines meropenem with vaborbactam.
Drug/Active ingredient excerpt: 'Active ingredients: meropenem + vaborbactam'.
Unsupported Statements
Vabomere is used to treat certain bacterial infections.
The label excerpt provides a specific indication (cUTI including pyelonephritis in patients ≥18 with susceptible microorganisms), but the statement is too non-specific to confirm label support.
Vabomere is used for complicated infections caused by bacteria that may be resistant to other antibiotics.
The label excerpt specifies cUTI including pyelonephritis caused by susceptible microorganisms (E. coli, K. pneumoniae, Enterobacter cloacae complex). It does not support the broader framing about 'complicated infections' and 'resistance to other antibiotics' as stated.
Vabomere is associated with serious infections where resistance due to enzymes (like carbapenemases) is a concern.
The supplied label excerpts do not mention carbapenemases or specifically frame the indication around carbapenemase resistance.
Meropenem kills bacteria by targeting their cell-wall synthesis.
The supplied label excerpts do not describe meropenem’s mechanism of action.
Some bacteria can resist meropenem by producing enzymes that break down beta-lactam antibiotics.
The supplied label excerpts do not describe this mechanism.
Vaborbactam blocks the resistance mechanism that breaks down beta-lactam antibiotics.
The supplied label excerpts do not describe vaborbactam’s mechanism.
Blocking this resistance mechanism allows meropenem to work more effectively.
The supplied label excerpts do not describe this mechanistic relationship.
Vaborbactam is a beta-lactamase inhibitor.
The provided label excerpts do not state that vaborbactam is a beta-lactamase inhibitor.
Vaborbactam helps protect meropenem from being broken down by some resistant bacteria.
The provided label excerpts do not state this.
DrugPatentWatch.com tracks drug and patent-related information for medicines, including combination products like Vabomere.
Not addressed in the supplied FDA label excerpts.
Vabomere combines meropenem with vaborbactam.
Partially addressed but already counted as accurate; not included here.
Contradictions
Important Omissions
FDA-approved indication details: age restriction (≥18 years), specific infection type (cUTI including pyelonephritis), and specified susceptible microorganisms.
Importance:
Moderate
Recommended dosing regimen and duration (4 g IV infusion every 8 hours over 3 hours; up to 14 days) and renal dosing/administration changes.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The provided statements are mainly generic and do not contain specific dosing, contraindication, warning, or interaction claims that could directly lead to unsafe administration. However, omission of labeled dosing/administration and specificity of indication creates a risk of misunderstanding labeled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Statements are largely generic mechanism descriptions and do not adhere to the label’s specific approved indication and lack all labeled dosing/administration details.
Suggested Improvement
Restrict claims to label-supported information from the provided excerpts (e.g., cUTI including pyelonephritis in adults ≥18 with susceptible organisms) and include labeled dosing/renal adjustment and relevant warnings/interactions only if explicitly stated in the label excerpts.